FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912381079> ?p ?o ?g. }

• W2912381079 abstract "PURPOSE The objectives of this study were to report the oncologic outcomes and the treatment-related toxicities after reirradiation (re-RT) for recurrent nasopharyngeal carcinoma (rNPC) at our institution and to apply a recently published prognostic model for survival in rNPC in our cohort. PATIENTS AND METHODS Thirty-two patients with rNPC treated at the authors' institution with re-RT were retrospectively reviewed. Treatment modalities for re-RT were intensity-modulated radiotherapy (n = 14), three-dimensional conformal radiotherapy (n = 9), single-fraction stereotactic radiosurgery (n = 6), fractionated stereotactic radiotherapy (n = 2), and high dose rate intracavitary brachytherapy (n = 1). Twenty-seven patients received re-RT with curative intent, whereas five patients were treated palliatively. RESULTS Median follow-up time was 15.5 months (range, 1 to 123 months) for the entire cohort and 20 months (range, 3 to 123 months) for patients treated with curative intent. For the entire cohort, median locoregional recurrence-free survival (LRRFS) was 14 months, with actuarial 1- and 2-year LRRFS estimates of 67.5% and 44.0%, respectively. Median overall survival (OS) time was 38 months, with actuarial 1- and 2-year estimates of 74.2% and 57.2%, respectively. For patients treated with curative intent, median LRRFS was not reached. Actuarial 1- and 2-year LRRFS estimates were 68.2% and 54.5%, respectively. Median OS time after curative intent re-RT was 42 months, with actuarial 1- and 2-year estimates of 75.4% and 63.8%, respectively. One- and 2-year OS estimates based on risk stratification were 68.6% for high risk compared with 80.8% for low risk and 34.3% for high risk compared with 70.7% for low risk, respectively ( P = .223). Three patients (9.4%) developed symptomatic temporal lobe necrosis. There was no reported grade 5 treatment-related toxicity. CONCLUSION Results of the study suggest that re-RT is an effective and safe salvage treatment strategy for rNPC. Re-RT to a maximum equivalent dose in 2-Gy fractions of 60 Gy may yield good LRRFS and translate to prolonged OS." @default.
• W2912381079 created "2019-02-21" @default.
• W2912381079 creator A5003890771 @default.
• W2912381079 creator A5004882376 @default.
• W2912381079 creator A5010807567 @default.
• W2912381079 creator A5015440396 @default.
• W2912381079 creator A5053939350 @default.
• W2912381079 creator A5062139453 @default.
• W2912381079 creator A5065990216 @default.
• W2912381079 date "2019-12-01" @default.
• W2912381079 modified "2023-10-10" @default.
• W2912381079 title "Reirradiation for Recurrent Nasopharyngeal Carcinomas: Experience From an Academic Tertiary Center in a Low- to Middle-Income Country" @default.
• W2912381079 cites W1976419684 @default.
• W2912381079 cites W1983600509 @default.
• W2912381079 cites W1996165106 @default.
• W2912381079 cites W2011506165 @default.
• W2912381079 cites W2011813809 @default.
• W2912381079 cites W2019419382 @default.
• W2912381079 cites W2029606539 @default.
• W2912381079 cites W2034763217 @default.
• W2912381079 cites W2043945205 @default.
• W2912381079 cites W2044189393 @default.
• W2912381079 cites W2060431068 @default.
• W2912381079 cites W2067283973 @default.
• W2912381079 cites W2074411517 @default.
• W2912381079 cites W2082548539 @default.
• W2912381079 cites W2088773564 @default.
• W2912381079 cites W2093953673 @default.
• W2912381079 cites W2102108448 @default.
• W2912381079 cites W2103246093 @default.
• W2912381079 cites W2117617147 @default.
• W2912381079 cites W2119836912 @default.
• W2912381079 cites W2130074302 @default.
• W2912381079 cites W2131531334 @default.
• W2912381079 cites W2139389882 @default.
• W2912381079 cites W2162486501 @default.
• W2912381079 cites W2167279270 @default.
• W2912381079 cites W2170967865 @default.
• W2912381079 cites W2177243765 @default.
• W2912381079 cites W2195731358 @default.
• W2912381079 cites W2240014735 @default.
• W2912381079 cites W2278841906 @default.
• W2912381079 cites W2342181295 @default.
• W2912381079 cites W2462243882 @default.
• W2912381079 cites W2483914858 @default.
• W2912381079 cites W2520142033 @default.
• W2912381079 cites W2528415183 @default.
• W2912381079 cites W2603127500 @default.
• W2912381079 cites W2604757939 @default.
• W2912381079 cites W2605933992 @default.
• W2912381079 cites W2735373040 @default.
• W2912381079 cites W2757798462 @default.
• W2912381079 cites W2762670725 @default.
• W2912381079 cites W2770782562 @default.
• W2912381079 cites W2786676459 @default.
• W2912381079 cites W79471600 @default.
• W2912381079 cites W2035824427 @default.
• W2912381079 doi "https://doi.org/10.1200/jgo.18.00191" @default.
• W2912381079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6426519" @default.
• W2912381079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30735433" @default.
• W2912381079 hasPublicationYear "2019" @default.
• W2912381079 type Work @default.
• W2912381079 sameAs 2912381079 @default.
• W2912381079 citedByCount "6" @default.
• W2912381079 countsByYear W29123810792019 @default.
• W2912381079 countsByYear W29123810792020 @default.
• W2912381079 crossrefType "journal-article" @default.
• W2912381079 hasAuthorship W2912381079A5003890771 @default.
• W2912381079 hasAuthorship W2912381079A5004882376 @default.
• W2912381079 hasAuthorship W2912381079A5010807567 @default.
• W2912381079 hasAuthorship W2912381079A5015440396 @default.
• W2912381079 hasAuthorship W2912381079A5053939350 @default.
• W2912381079 hasAuthorship W2912381079A5062139453 @default.
• W2912381079 hasAuthorship W2912381079A5065990216 @default.
• W2912381079 hasBestOaLocation W29123810791 @default.
• W2912381079 hasConcept C126322002 @default.
• W2912381079 hasConcept C141071460 @default.
• W2912381079 hasConcept C2777416452 @default.
• W2912381079 hasConcept C2778997737 @default.
• W2912381079 hasConcept C2779709957 @default.
• W2912381079 hasConcept C2989005 @default.
• W2912381079 hasConcept C3019894029 @default.
• W2912381079 hasConcept C509974204 @default.
• W2912381079 hasConcept C71924100 @default.
• W2912381079 hasConcept C72563966 @default.
• W2912381079 hasConceptScore W2912381079C126322002 @default.
• W2912381079 hasConceptScore W2912381079C141071460 @default.
• W2912381079 hasConceptScore W2912381079C2777416452 @default.
• W2912381079 hasConceptScore W2912381079C2778997737 @default.
• W2912381079 hasConceptScore W2912381079C2779709957 @default.
• W2912381079 hasConceptScore W2912381079C2989005 @default.
• W2912381079 hasConceptScore W2912381079C3019894029 @default.
• W2912381079 hasConceptScore W2912381079C509974204 @default.
• W2912381079 hasConceptScore W2912381079C71924100 @default.
• W2912381079 hasConceptScore W2912381079C72563966 @default.
• W2912381079 hasLocation W29123810791 @default.
• W2912381079 hasLocation W29123810792 @default.
• W2912381079 hasLocation W29123810793 @default.
• W2912381079 hasLocation W29123810794 @default.
• W2912381079 hasOpenAccess W2912381079 @default.

• next